Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Porta

Internal Medicine Shreveport, LA Medical Doctor

NPI 1275890436 CMS profile 1026957

1501 Kings Hwy, Lsuhsc Dept. Of Gastroenterology, Shreveport, LA 71130

Open in the dashboard

General payments

$4,913

289 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$42,321

4 holdings reported · through program year 2025

Through program year 2025, Mark Porta of Shreveport, LA is reported in the CMS Open Payments database as having received $4,913 across 289 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $42,321 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,042 66
2024 General $939 61
2023 General $807 49
2022 General $674 47
2021 General $423 27
2020 General $447 26
2019 General $582 13
2024 Ownership $19,940 1
2023 Ownership $19,940 1
2022 Ownership $1,252 1
2021 Ownership $1,188 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Porta
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mark Porta were reported at $1,042. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mark Porta Internal Medicine median Middle half National median
2019 $582 $159 $48–$570 $163
2020 $447 $119 $33–$402 $114
2021 $423 $135 $37–$521 $132
2022 $674 $141 $42–$496 $149
2023 $807 $149 $45–$519 $160
2024 $939 $154 $47–$537 $164
2025 $1,042 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $807 66 payments
  2. Boston Scientific Corporation $636 12 payments
  3. Janssen Biotech, Inc. $635 40 payments
  4. Celgene Corporation $489 34 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $457 27 payments
  6. Ardelyx, Inc. $357 20 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $347 20 payments
  8. Genzyme Corporation $138 7 payments
  9. Ferring Pharmaceuticals Inc. $101 7 payments
  10. Madrigal Pharmaceuticals $88 4 payments
  11. Other $858 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,558 287 payments
  2. Travel and Lodging $356 2 payments
Products named General payments · program years 2019–2025
  1. STELARA $511 34 payments
  2. ZEPOSIA $448 32 payments
  3. RINVOQ $440 43 payments
  4. XIFAXAN $411 24 payments
  5. GENERAL BILIARY DEVICES $390 4 payments
  6. IBSRELA $357 20 payments
  7. ENTYVIO $293 17 payments
  8. SKYRIZI Immunology $201 22 payments
  9. SKYRIZI Immunology $171 17 payments
  10. LINZESS $157 9 payments
  11. Other $2,153 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,139

Median for Internal Medicine: 777

Drug cost

$136,932

Median for Internal Medicine: $73,373

Branded share of claims

20.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 14 $41,370
Relistor Methylnaltrexone Bromide Brand 17 $33,558
Linzess Linaclotide Brand 42 $30,304
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 53 $8,663
Omeprazole Generic 317 $4,258
Colestipol Hcl Generic 50 $3,027
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 21 $2,870
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 43 $2,753
Famotidine Generic 124 $1,725
Sucralfate Generic 44 $1,494

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$99,619

Of which drugs: $55,952

Medicare patients

214

Average age 72

Services billed

4,984

110 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 39%
Ischemic heart disease 35%
Chronic kidney disease 32%
Depression 28%
Heart failure 23%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 12 3,600 $52,389

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $78
  • Regeneron Healthcare Solutions, Inc. $25
$103 — —
STELARA
  • Janssen Biotech, Inc. $97
$97 — —
RINVOQ
  • AbbVie, Inc. $95
$95 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $84
$84 — 3,600
SKYRIZI
  • AbbVie, Inc. $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

289 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record